Discounted Cash Flow (DCF) Analysis Levered

Strongbridge Biopharma plc (SBBP)

$2

+0.03 (+1.52%)
All numbers are in Millions, Currency in USD

Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
Revenue (%)
Operating Cash Flow ----------
Operating Cash Flow (%)
Capital Expenditure ----------
Capital Expenditure (%)
Free Cash Flow ----------

Weighted Average Cost Of Capital

Share price $ 2
Beta 1.596
Diluted Shares Outstanding 56.11
Cost of Debt
Tax Rate 0.03
After-tax Cost of Debt 7.34%
Risk-Free Rate
Market Risk Premium
Cost of Equity 11.117
Total Debt 18.19
Total Equity 112.21
Total Capital 130.40
Debt Weighting 13.95
Equity Weighting 86.05
Wacc

Build Up Free Cash Flow

Year
A/P
2016
Actual
2017
Actual
2018
Actual
2019
Actual
2020
Actual
2021
Projected
2022
Projected
2023
Projected
2024
Projected
2025
Projected
Revenue ----------
Operating Cash Flow ----------
Capital Expenditure ----------
Free Cash Flow ----------
WACC
PV LFCF -----
SUM PV LFCF -

Terminal Value

Growth in perpetuity method:
Long-term growth rate
WACC (%) 10.59
Free cash flow (t + 1) -
Terminal Value -
Present Value of Terminal Value -

Intrinsic Value

Enterprise Value -
Net Debt -69.33
Equity Value -
Shares Outstanding 56.11
Equity Value Per Share -